摘要
本文用免疫组化法对15例乳腺癌做了多药耐药基因产物P17。及谷航计肽S一转移酶（GST。）以及雌孕激素受体（ER，PR）的检测。浸润性导管瘤14例，粘液腺癌1例。检测结果雌孕激素受体共同表达率为667％（IO门5），巳？。过度表达为“7（10／15）．GSTx过度表达为553％（8／15）。ER、PR表达与肿瘤的分化程度有关，即分化好的乳腺癌标记率较高，提示预后较好。结果表明多数乳腺癌表达雌孕激素受体，提示对内分泌治疗有效。P；0，GST，不仅为乳腺癌标记物，而且也提示了多数乳腺癌对亲脂类及烷化剂类化疗药可能具有耐药性。因此时过度表达的乳腺癌临床上应慎用此类化疗药。
MDRl-P170(multidrug resistance, P-glycoprotein-170). GST (Glutathione-S-Transferase ), ER (Estrogen Receptors)and PR (Frogesterone Receptors) were studied in 15 cases of breast carcinoma by Immunohistochemical technlque. The results showed positive rate Qf both ER, PR and P170 was 10/15 (66. 7% ), and that of GST was 8/15 (53. 3% ). It is suggested that most patients with breast carcinoma was effective for endocrine therapy. Those patients of expression of the P170 and GST might be resistent to lipophil or alkylating agent.
关键词
耐药基因
雌激素受体
孕激素受体
乳腺肿瘤
Multidrug resistance gene
Estrogen receptors
Progesterone receptors
Breast neoplasms
